Literature DB >> 20439469

A comparative study of the effects of the intravenous self-administration or subcutaneous minipump infusion of nicotine on the expression of brain neuronal nicotinic receptor subtypes.

Milena Moretti1, Manolo Mugnaini, Michela Tessari, Michele Zoli, Annalisa Gaimarri, Irene Manfredi, Francesco Pistillo, Francesco Clementi, Cecilia Gotti.   

Abstract

Long-term nicotine exposure changes neuronal acetylcholine nicotinic receptor (nAChR) subtype expression in the brains of smokers and experimental animals. The aim of this study was to investigate nicotine-induced changes in nAChR expression in two models commonly used to describe the effects of nicotine in animals: operant (two-lever presses) intravenous self-administration (SA) and passive subcutaneous nicotine administration via an osmotic minipump (MP). In the MP group, alpha4beta2 nAChRs were up-regulated in all brain regions, alpha6beta2* nAChRs were down-regulated in the nucleus accumbens (NAc) and caudate-putamen, and alpha7 nAChRs were up-regulated in the caudal cerebral cortex (CCx); the up-regulation of alpha4beta2alpha5 nAChRs in the CCx was also suggested. In the SA group, alpha4beta2 up-regulation was lower and limited to the CCx and NAc; there were no detectable changes in alpha6beta2* or alpha7 nACRs. In the CCx of the MP rats, there was a close correlation between the increase in alpha4beta2 binding and alpha4 and beta2 subunit levels measured by means of Western blotting, demonstrating that the up-regulation was due to an increase in alpha4beta2 proteins. Western blotting also showed that the increase in the beta2 subunit exceeded that of the alpha4 subunit, suggesting that a change in alpha4beta2 stoichiometry may occur in vivo as has been shown in vitro. These results show that nicotine has an area-specific effect on receptor subtypes, regardless of its administration route, but the effect is quantitatively greater in the case of MP administration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20439469     DOI: 10.1124/mol.110.064071

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  27 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  Adolescent nicotine exposure transiently increases high-affinity nicotinic receptors and modulates inhibitory synaptic transmission in rat medial prefrontal cortex.

Authors:  Danielle S Counotte; Natalia A Goriounova; Milena Moretti; Marek T Smoluch; Hubertus Irth; Francesco Clementi; Anton N M Schoffelmeer; Huibert D Mansvelder; August B Smit; Cecilia Gotti; Sabine Spijker
Journal:  FASEB J       Date:  2012-02-03       Impact factor: 5.191

3.  Regulation of α4β2α5 nicotinic acetylcholinergic receptors in rat cerebral cortex in early and late adolescence: Sex differences in response to chronic nicotine.

Authors:  Bethany G Hoegberg; Ermelinda Lomazzo; Norman H Lee; David C Perry
Journal:  Neuropharmacology       Date:  2015-08-10       Impact factor: 5.250

Review 4.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

5.  Stimulation of nicotine reward and central cholinergic activity in Sprague-Dawley rats exposed perinatally to a fat-rich diet.

Authors:  Irene Morganstern; Olga Lukatskaya; Sang-Ho Moon; Wei-Ran Guo; Jane Shaji; Olga Karatayev; Sarah F Leibowitz
Journal:  Psychopharmacology (Berl)       Date:  2013-07-09       Impact factor: 4.530

6.  An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

Authors:  Christopher G Baddick; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2011-05-10       Impact factor: 5.858

7.  Differential effects of withdrawal from intermittent and continuous nicotine exposure on reward deficit and somatic aspects of nicotine withdrawal and expression of α4β2* nAChRs in Wistar male rats.

Authors:  Svetlana Semenova; Xinchun Jin; Tristan D McClure-Begley; Matthew Philip Tadman; Michael J Marks; Athina Markou
Journal:  Pharmacol Biochem Behav       Date:  2018-06-14       Impact factor: 3.533

8.  The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.

Authors:  Tanuja Bordia; J Michael McIntosh; Maryka Quik
Journal:  J Neurochem       Date:  2013-03-03       Impact factor: 5.372

9.  r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement.

Authors:  Joshua S Beckmann; Andrew C Meyer; M Pivavarchyk; David B Horton; Guangrong Zheng; Andrew M Smith; Thomas E Wooters; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

10.  Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.

Authors:  G Patrick Hussmann; Kristen E DeDominicis; Jill R Turner; Robert P Yasuda; Jacquelyn Klehm; Patrick A Forcelli; Yingxian Xiao; Janell R Richardson; Niaz Sahibzada; Barry B Wolfe; Jon Lindstrom; Julie A Blendy; Kenneth J Kellar
Journal:  J Neurochem       Date:  2014-02-07       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.